Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 1Q11

U.S. product sales in the quarter increased 4% to $2.8 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen1Q11

1Q Revenues: $3.7 billion (+3%)

1Q Earnings: $1.1 billion (-4%)

Comments: U.S. product sales in the quarter increased 4% to $2.8 billion. International sales were down 1% to $840 million. Aranesp sales were down 7% to $580 million and Epogen sales were down 14% to $535 million, due to decline in demand. Neulasta and Neupogen sales were up 4% to $1.2 billion. Enbrel sales increased 9% to $875 million. Sales of Sensipar / Mimpara were $187 million (+4%). R&D expenses were up 14% to $703 million in the quarter. Sales of Prolia in the quarter were $27 million. U.S. sales of XGEVA were $42 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters